1. Puerarin Inhibits oxLDL-Induced Macrophage Activation and Foam Cell Formation in Human THP1 Macrophage
- Author
-
Yuhan Lin, Yueping Shi, Ming-Sheng Zhou, Xiaojie Li, Heng Zhang, Zhenhua Zhai, Yao Li, Weihong Li, and Hongyu Zhou
- Subjects
Article Subject ,CD36 ,lcsh:Medicine ,Pharmacology ,General Biochemistry, Genetics and Molecular Biology ,Proinflammatory cytokine ,Cell Line ,chemistry.chemical_compound ,Downregulation and upregulation ,Puerarin ,Humans ,Drug Interactions ,Scavenger receptor ,Cells, Cultured ,Foam cell ,General Immunology and Microbiology ,biology ,Dose-Response Relationship, Drug ,Chemistry ,Macrophages ,lcsh:R ,General Medicine ,Macrophage Activation ,Isoflavones ,Lipoproteins, LDL ,IκBα ,Immunology ,TLR4 ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Inflammation Mediators ,Foam Cells ,Research Article - Abstract
Puerarin, an isoflavone derived from Kudzu roots, has been widely used for treatment of cardiovascular and cerebral vascular diseases in China and other Asian countries. However, the underlying mechanisms are largely unknown. The present study investigated whether puerarin inhibited atherogenic lipid oxLDL-mediated macrophage activation and foam cell formation in human THP1 macrophage. Treatment with oxLDL significantly increased the mRNA expression of proinflammatory cytokines tumor necrosis factorα(TNFα, 160%) and interleukin (IL) 1β(13 fold) accompanied by upregulation of toll-like receptor 4 (TLR4, 165%) and the ratio of phospho-IκBα/IκBαin THP1 macrophage. Puerarin dose-dependently prevented an increase in oxLDL-induced proinflammatory gene expression with downregulation of TLR4 and the ratio of phospho-IκBα/IκBα. Furthermore, puerarin prevented oxLDL-mediated lipid deposition and foam cell formation associated with downregulation of scavenger receptor CD36. Flow cytometry analysis showed that puerarin reduced the number of early apoptotic cells of macrophages induced by oxLDL. Our results show that puerarin has anti-inflammatory and antiatherogenic effects in vitro; the underlying mechanisms may involve the inhibition of TLR4/NFκB pathway and downregulation of CD36 expression. The results from the present study provide scientific evidence and may expand our armamentarium to use puerarin for prevention and treatment of cardiovascular and atherosclerotic diseases.
- Published
- 2015